Medina-De la Garza CE, Salvador Flores-Torres A, García-Hernández M, de Los Ángeles Castro-Corona M. Diethylcarbamazine as potential treatment of COVID-19 lung fibrosis.
Med Hypotheses 2022;
160:110774. [PMID:
35095174 PMCID:
PMC8788098 DOI:
10.1016/j.mehy.2022.110774]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2021] [Revised: 12/13/2021] [Accepted: 01/10/2022] [Indexed: 11/29/2022]
Abstract
Diethylcarbamazine, the antiparasitic drug, also possesses anti-inflammatory and immunomodulatory activities. The anti-fibrotic activity of diethylcarbamazine makes it a potential candidate to treat coronavirus disease 2019 (COVID-19)-related pulmonary fibrosis. Experimental and clinical studies should assess this possible effect.
Collapse